Open access
Aug 2026
Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan
The safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified, and inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD.
K. Fujihara, Shinya Hirota, Muneyoshi Kudo et al.
· Neurological Therapeutics · 0 citations